Today, The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) detailed data that shows Dysport offers a significant efficacy advantage over the well established Botox Cosmetic for treating crow's feet. The study was presented today during a scientific session at the AAFPRS 2010 Annual Fall Meeting.
Investigators studied 90 subjects, assessing contraction at 30 days following treatment when compared with day 0. The internally controlled double-blind study found a greater efficacy of action for Dysport over Botox. "Botox has long been considered the gold standard of injectables, so this data showing Dysport's stronger efficacy is compelling," said Dr. Corey Maas, AAFPRS Group Vice President for Public and Regulatory Affairs.
Dysport gained approval from the US FDA for cosmetic use in July of 2009, while Botox has had a strong hold on the injectable toxin market since April 2002. Xeomin is another botulinum toxin injectable that just gained approval in the US for the treatment of cervical dystonia, but many physicians plan to use it off-label as a cosmetic treatment, much like Botox and Dysport were at first.
The study concluded that Dysport offers a quantifiable and demonstrable advantage in wrinkle shortening and hyperfunctional frown lines compared to Botox Cosmetic in the treatment of crow's feet. Study investigators recommend further studies in additional facial regions to confirm the data.